HAEK.HM Haemato AG
- Market cap
- EUR 69.2M
- P/E
- 6.5x
- P/B
- 0.66x
- ROE
- 5.6%
- Dividend yield
- 8.31%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2022.
Is HAEK.HM undervalued?
Graham numberHAEK.HM trades 56.5% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Haemato AG fundamental analysis
No fundamental analysis for Haemato AG yet.
Haemato AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Haemato AG
HAEMATO AG, together with its subsidiaries, operates in the pharmaceutical sector in Germany. It operates through Specialty Pharma and Lifestyle & Aesthetics segments. The company engages in the development, acquisition, licensing, and distribution of prescription drugs and OTC products, and special cosmetics, as well as dietary supplements. It also provides pharmaceuticals in the areas of HIV/AIDS, neurology, oncology, and rheumatology diseases. In addition, it develops, ma…
Full company profileHaemato AG financial statements
Haemato AG annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 |
|---|---|---|
| Income Statement | ||
| Revenue | 285M | 248M |
| Gross Profit | 30.7M | 21.6M |
| Operating Income | 11.2M | 8.30M |
| EBITDA | 11.3M | 12.2M |
| Net Income | 6.53M | 8.19M |
| EPS | 1.25 | 1.57 |
| Balance Sheet | ||
| Total Assets | 182M | 177M |
| Total Liabilities | 37.3M | 29.4M |
| Shareholders' Equity | 145M | 147M |
| Cash & Short-term Investments | 25.6M | 23.8M |
| Cash Flow | ||
| Operating Cash Flow | 14.1M | 19.7M |
| Capital Expenditure | 327K | 1.09M |
| Free Cash Flow | 13.7M | 18.6M |
| Ratios | ||
| ROE | 4.5% | 5.6% |
| ROA | 3.6% | 4.6% |
| Net Profit Margin | 2.3% | 3.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Haemato AG dividends
- Dividend yield
- 8.31%
- Forward dividend
- 0.04 EUR
- Payout ratio
- 70.2%
- Ex-dividend date
- Jul 8, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2022 | EUR 5.75M | 1.10 | 70.2% |
| 2021 | EUR 2.76M | 0.53 | 42.2% |
| 2020 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Sep 2, 2020.
Who owns Haemato AG
Ownership data of Haemato AG is not available yet.
Haemato AG company profile
- Company name
- Haemato AG
- Ticker
- HAEK.HM
- ISIN
- DE000A289VV1
- Exchange
- Hamburg Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 76
- Fiscal year end
- December
- Address
- Lilienthalstrasse 3a, Schönefeld, Germany, 12529
- Phone
- 49 30 897 30 86 70
- Website
- haemato.ag
About Haemato AG
HAEMATO AG, together with its subsidiaries, operates in the pharmaceutical sector in Germany. It operates through Specialty Pharma and Lifestyle & Aesthetics segments. The company engages in the development, acquisition, licensing, and distribution of prescription drugs and OTC products, and special cosmetics, as well as dietary supplements. It also provides pharmaceuticals in the areas of HIV/AIDS, neurology, oncology, and rheumatology diseases. In addition, it develops, manufactures, and distributes diagnostic tests under the HAEMATO brand; and cosmetics under the brand M1 SELECT, as well as supplies third party-products. The company serves clinics, pharmacies, wholesalers, and medical test centers. The company was founded in 1993 and is based in Schönefeld, Germany. HAEMATO AG operates as a subsidiary of M1 Kliniken AG.
Haemato AG management
2- Mr. Thomas EhmannMD & Member of Management Board
- Dr. Robin Wagner-FabischMD & Member of Management Board